TG Therapeutics (TGTX) Competitors $36.29 +0.89 (+2.51%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$36.78 +0.48 (+1.34%) As of 07:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMCShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in TEVA or TGTX? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is TEVA or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-7.74% 45.44% 6.95% TG Therapeutics 10.13%18.88%7.05% Which has stronger earnings & valuation, TEVA or TGTX? TG Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.84TG Therapeutics$329M17.51$23.38M$0.24151.21 Do analysts rate TEVA or TGTX? Teva Pharmaceutical Industries presently has a consensus target price of $24.13, suggesting a potential upside of 41.33%. TG Therapeutics has a consensus target price of $40.80, suggesting a potential upside of 12.43%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, TEVA or TGTX? Teva Pharmaceutical Industries has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Does the media favor TEVA or TGTX? In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.83 beat Teva Pharmaceutical Industries' score of 0.74 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTG Therapeutics beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.62B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio151.2121.3126.2319.90Price / Sales17.51278.47413.23113.66Price / Cash295.0941.4736.1356.90Price / Book25.387.518.045.38Net Income$23.38M-$55.05M$3.15B$248.50M7 Day Performance-4.37%2.07%1.44%2.04%1 Month Performance-0.33%4.84%3.62%4.84%1 Year Performance93.13%5.37%34.68%20.23% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics3.7706 of 5 stars$36.29+2.5%$40.80+12.4%+98.2%$5.62B$329M151.21290TEVATeva Pharmaceutical Industries4.0876 of 5 stars$16.96+0.1%$24.44+44.1%+3.0%$19.45B$16.54B-14.7536,830SMMTSummit Therapeutics2.4753 of 5 stars$20.39-0.8%$35.09+72.1%+200.0%$15.14B$700K-59.97110Analyst ForecastITCIIntra-Cellular Therapies0.9247 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8892 of 5 stars$20.68-2.3%$39.17+89.4%-17.9%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8228 of 5 stars$15.31+0.5%$16.95+10.7%-2.3%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5796 of 5 stars$175.78-0.6%$220.67+25.5%+27.0%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0627 of 5 stars$8.85-0.2%$10.40+17.5%-10.5%$10.39B$14.74B-2.7932,000QGENQiagen3.7836 of 5 stars$46.72-0.1%$47.74+2.2%+22.8%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3651 of 5 stars$25.67-0.9%$46.61+81.6%-74.1%$9.93B$3.14B-2.945,800Trending NewsOptions VolumeBPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.29B$508.82M-51.98640High Trading Volume Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
